Astec Lifesciences
Astec Lifesciences (ASTEC) share price was ₹602.95 at the 28 Oct 2026 close; market capitalisation ₹1,344 Cr; sector Chemicals. The share price fell 11.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 8.2% year on year to ₹83.6 Cr and net profit was −₹19 Cr, against −₹33 Cr a year earlier (compared with Jun 2025). Promoters held 71.96% of Astec Lifesciences in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 30/100 (Poor) as of 28 Oct 2026.
Key Fundamentals
MicrocapFertilizers & AgrochemicalsChemicalsPrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Consolidated · TTM
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹536.40 | 22.40 | 45,281 Cr | 1.30 | 1.16% | 5.38% | 10.85% | 53,683 Cr | 2,323 Cr | |
| ₹2,055.00 | 26.76 | 31,178 Cr | 2.78 | 0.72% | 11.76% | 14.68% | 6,914 Cr | 1,164 Cr | |
| ₹335.45 | 28.87 | 16,744 Cr | 4.53 | 0.38% | 16.00% | 20.98% | 3,409 Cr | 581 Cr | |
| ₹3,282.10 | 20.15 | 14,750 Cr | 4.97 | 4.59% | 23.24% | 27.93% | 5,761 Cr | 733 Cr | |
| ₹683.20 | 9.84 | 6,164 Cr | 1.97 | 2.31% | 21.71% | 25.26% | 5,464 Cr | 626 Cr | |
| ₹887.70 | 14.91 | 3,957 Cr | 2.35 | 0.23% | 21.17% | 27.37% | 2,071 Cr | 268 Cr | |
| ₹188.72 | 17.14 | 3,670 Cr | 1.67 | 1.58% | 9.68% | 12.75% | 2,631 Cr | 214 Cr | |
| Astec Lifesciences (this company) | ₹602.95 | — | 1,344 Cr | 4.01 | 0.23% | -20.69% | -10.51% | 444 Cr | -67 Cr |
| Median 8 companies | ₹643.08 | 20.15 | 10,457 Cr | 2.57 | 0.94% | 13.88% | 17.83% | 4,437 Cr | 604 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
7- Stock is trading at 4.05 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -4.18% over past five years.
- Company has a low return on equity of -26.0% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.3.21 Cr.
- Company has high debtors of 202 days.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
0 of 1 analyst rates Buy, 0 Hold, 1 Sell.
Updated 28 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin -0.8% · Jun 2026
Analyst Forecasts
Analyst consensus here uses a different definition from reported ebitda (they differ 49.2× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
| Expenses | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 |
| Operating Profit | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 | -7 | 4 | 9 | -1 |
| OPM % | 2.2% | -3.1% | -36% | 8% | -67% | -20% | -6% | 4.6% | -12% | -9% | 3.2% | 6% | -0.8% |
| Other Income | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | -1 | 3 | 1 |
| Interest | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 |
| PBT | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 | -24 | -16 | -8 | -19 |
| Tax % | -26% | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% | 0% | 0% | -2% | 0% |
| Net Profit | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 |
| EPS (₹) | -3.66 | -6 | -10.86 | -0.43 | -17.73 | -17.21 | -18.03 | -7.18 | -14.75 | -10.96 | -7.05 | -3.48 | -8.4 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 441 |
| Expenses | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 453 | 435 |
| Operating Profit | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -4 | 6 |
| OPM % | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1.3% | -17% | -1% | 1.3% |
| Other Income | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 3 | 3 |
| Interest | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 35 | 31 |
| Depreciation | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 | 44 |
| PBT | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -81 | -67 |
| Tax % | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% | 0% | — |
| Net Profit | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 | -67 |
| EPS (₹) | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -36.32 | -29.89 |
| Div. Payout % | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 368 |
| Borrowings | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 449 |
| Other Liabilities | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
| Fixed Assets | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 |
| CWIP | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 463 |
| Total Assets | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | -81 |
| Investing | -19 | -17 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | -4 |
| Financing | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net Cash Flow | 0 | 2 | 1 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Free Cash Flow | -13 | -39 | -1 | 15 | -37 | 123 | -111 | -80 | -42 | -125 | -24 | -86 |
| CFO/EBITDA | 19 | -24 | 41 | 116 | 41 | 219 | 13 | 34 | 104 | -211 | 20 | 1,796 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 | 202 |
| Inventory Days | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 | 169 |
| Days Payable | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 | 107 |
| Cash Conversion Cycle | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 | 263 |
| Working Capital Days | 19 | -28 | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 | -56 |
| ROCE % | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% | -5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astec Lifesciences insights
64 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Astec Lifesciences
What does Astec Lifesciences Ltd do?
Where is Astec Lifesciences Ltd (ASTEC) listed?
Which sector does Astec Lifesciences Ltd belong to?
What is the market capitalisation of Astec Lifesciences Ltd?
What is the 52-week high and low of Astec Lifesciences Ltd?
Does Astec Lifesciences Ltd pay dividends?
What is the Return on Equity (ROE) of Astec Lifesciences Ltd?
Company Information
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTEC.md for Astec Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.